

Eurofins Genomics adopts Olink® technology to Enhance Proteomics Research and Boost Precision Medicine Initiatives**

Ebersberg, Germany, 12th September, 2023 - Eurofins Genomics is thrilled to announce its strategic initiative with Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK). This partnership aims to enrich our offerings in research, population health, and regulated clinical trials through the integration of Olink technology.

Olink’s high-multiplex technique is unparalleled in quantifying protein biomarkers, requiring only minimal clinical sample volume. The method boasts exceptional sensitivity, specificity, and a vast dynamic range. With the inclusion of the Olink Explore platform in the Eurofins Genomics portfolio, clients will benefit from enhanced capabilities in population health, clinical trials, and pre-clinical developments. This initiative's prime objective is to pave the way for the large-scale discovery and validation of proteomics across a wide array of biological pathways and sample matrices.

Jon Heimer, CEO of Olink, stated, “We are immensely pleased to see the Olink Explore platform being utilised by Eurofins Genomics, one of the world’s leading multiomic service providers, that contribute to a safer and healthier world by providing their customers with innovative and high-quality services. With their extensive presence in both the pharma and population health spaces, Eurofins Genomics will apply Olink technology across a broad spectrum of new therapeutic research fields to improve understanding of the development, progression, and outcome of disease.”

Eurofins Genomics will harness Olink Explore technology in three areas:

1. Expanding genetic biomarker discovery with proteomics enabling proteogenomics
2. Increasing offerings in pre-clinical development and clinical trials with protein biomarkers
3. Strengthening its foothold in population health and consumer genomics.

Having provided top-tier multi-omics services, covering genomics, transcriptomics, and epigenomics, for many years, Eurofins Genomics is excited to expand its suite of offerings to proteomics. Through the partnership with Olink, Eurofins Genomics will now introduce proteomics to its extensive portfolio, leveraging existing sequencing capabilities and qPCR equipment.

For further information please contact:

Julian Schloßmacher

Head of Marketing and Communication Eurofins Genomics Europe

Julian.schlossmacher@genomics.eurofinseu.com

<https://eurofinsgenomics.com>

About Eurofins Genomics:

Eurofins Genomics represents the genomic division within the Eurofins Scientific Group. With facilities in Europe, the United States and Asia, Eurofins Genomics is an internationally leading provider of DNA sequencing and genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The European branch is headquartered in Ebersberg, Germany. For further information, please visit www.eurofinsgenomics.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agrosience as well as Contract Research services. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, BioPharma Contract Development and Manufacturing, advanced material sciences and has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 62,000 staff across a network of 940 laboratories in 61 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

About Olink Holding AB:

[Olink Holding AB](#) (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.